Third Circuit upholds denial of diet-drug settlement claim

[JURIST] The US Court of Appeals for the Third Circuit [official website; JURIST news archive] on Thursday ruled [opinion, PDF] that a claimant had produced insufficient medical evidence to recover from a settlement fund established to compensate those harmed by the weight-loss medication known as fen-phen [FDA backgrounder]. The Philadelphia-based court affirmed a decision by the US District Court for the Eastern District of Pennsylvania [official website] denying Gay Patterson's claim against the AHP Settlement Trust [trust website] as lacking a reasonable medical basis. Patterson alleges she suffers from moderate mitral regurgitation [Mayo Clinic backgrounder], or a leaky heart valve - a condition that would qualify her for compensation from the trust. She argued that the district court had erred by failing to accept a single frame of an echocardiogram as sufficient evidence of her condition and by relying instead on an auditing cardiologist's visual assessment of an echocardiogram. Chief Circuit Judge Anthony J. Scirica [official profile] wrote for the three-member panel:

We cannot agree with Patterson's argument that, in a borderline case such as this, the measurement of a single frame in an echocardiogram, without evidence showing that the
depicted jet is a true regurgitant jet, i.e., representative of the claimant’s actual level of mitral regurgitation, constitutes a reasonable medical basis for recovering Matrix compensation. To hold otherwise would permit claimants whose echocardiograms show an aberrant jet in a single frame to recover payment from the Trust.
Further, the court found that a physician's "eyeball" assessment is proper when an echocardiogram clearly indicates that the claimant's level of valve leakage is consistent with that of the general population.

The settlement fund resulted from class-action litigation [case backgrounder] against the company now known as Wyeth Pharmaceuticals [corporate website], which pulled its diet drugs Pondimin (fenfluramine) and Redux (dexfenflura) off the market [FDA press release] in 1997. Earlier that year, a Mayo Clinic study [text] linked fen-phen, a combination of the Wyeth drugs with the medication phentermine, to a rare heart-valve condition. The Judicial Panel on Multidistrict Litigation later transferred all diet-drug cases in federal court to Pennsylvania's Eastern District. The court approved [order text] a settle agreement [materials] in 2000, leading to the establishment of the trust.


 

About Paper Chase

Paper Chase is JURIST's real-time legal news service, powered by a team of 30 law student reporters and editors led by law professor Bernard Hibbitts at the University of Pittsburgh School of Law. As an educational service, Paper Chase is dedicated to presenting important legal news and materials rapidly, objectively and intelligibly in an accessible format.

© Copyright JURIST Legal News and Research Services, Inc., 2013.